Carter Gould
Stock Analyst at Cantor Fitzgerald
(1.59)
# 1280
Out of 5,325 analysts
222
Total ratings
46.03%
Success rate
6.73%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb | Reiterates: Neutral | 55 55 | 48.52 | 13.36% | 16 | Apr 23, 2025 | |
VRTX Vertex Pharmaceutica... | Assumes: Overweight | 535 | 492.8 | 8.56% | 2 | Apr 22, 2025 | |
REGN Regeneron Pharmaceut... | Assumes: Overweight | 695 | 587.8 | 18.24% | 19 | Apr 22, 2025 | |
PFE Pfizer | Initiates Coverage On: Neutral | 24 | 22.38 | 7.24% | 15 | Apr 22, 2025 | |
PCVX Vaxcyte | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 85 | 78.74 | 7.95% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 975 | 830.32 | 17.42% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 125 | 106.44 | 17.44% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 210 | 177.17 | 18.53% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 165 | 103.27 | 59.78% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 16.7 | 19.76% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 190 180 | 118.2 | 52.28% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 300 315 | 278.07 | 13.28% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 100 | 72.72 | 37.51% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 3 | 0.76 | 294.74% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 3 | 0.82 | 265.85% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 1.38 | 552.17% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 95 | 37.99 | 150.07% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 20 | 21.09 | -5.17% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 73 | 63.68 | 14.64% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.33 | 203.03% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 110 172 | 172.36 | -0.21% | 7 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1.17 | 925.64% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 2 | 0.9 | 66.67% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 15 | n/a | n/a | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 3 | 0.36 | 525% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 392 380 | 219.37 | 73.22% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 150 180 | 178.75 | 0.7% | 4 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 82 | 58.05 | 41.26% | 3 | Jan 16, 2019 |